Thursday, November 5, 2026Eastern Time · Updated through the dayRSS

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Analyst warns Zealand Pharma’s next survodutide study may disappoint on tolerability again

MH

By Maren Holt · Senior Reporter, GLP-1

Nov 5 07:58 ETSource: MedWatch

From the source

Analyst warns Zealand Pharma’s next survodutide study may disappoint on tolerability again

Read at medwatch.com

Source URL https://medwatch.com/News/Pharma___Biotech/article19805706.ece

Prescribed peptides from $99/moSee all →